Prognostic role of E-cadherin in patients with advanced serous ovarian cancer

Archives of Gynecology and Obstetrics

Volumn 287, Issue 6, 2013, Pages 1219-1224

  Bačić, Boris ^a   Haller, Herman ^b   Mrklić, Ivana ^a   Košta, Vana ^c   Čarić, Ana ^c   Tomić, Snježana ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c UNIVERSITY OF SPLIT   (Croatia)

Author keywords

E cadherin; Immunohistochemistry; Ovarian cancer; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; UVOMORULIN;

ADULT; ADVANCED CANCER; ADVANCED SEROUS OVARIAN CANCER; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MITOSIS; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE DIFFERENTIATION; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84878108291     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2684-9     Document Type: Article

References (29)

1. Ozols RF, Rubin SC, Thomas GM, Robboy SJ (2000) Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology, 3rd edn. Lippincott, Williams and Wilkins, Philadelphia, pp 895-896
2. Seidman JD, Kurman RJ (2003) Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 17(4):909-925 vii
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10-30
4. Shimamura T, Une Y, Nakajima Y, Sato N, Matsushita M, Kamiyama T, Haneda T, Nakanishi K, Akabane H, Tomioka N et al (1995) Advantages and disadvantages of the intraarterial chemotherapy using a reservoir as postoperative adjuvant therapy for hepatocellular carcinoma. Gan To kagaku Ryoho Cancer Chemother 22(11):1511-1514
5. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS (2011) Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 179(1):400-410. doi: 10.1016/j.ajpath.2011.03.028
6. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Hofler H, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F (2011) Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 11:509. doi: 10.1186/1471-2407-11-509
7. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 17(6):1642-1648. doi: 10.1245/s10434-010-0964-9
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026
9. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496-504
10. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM (2012) Reclassification of serous ovarian carcinoma by a 2-tier system: a gynecologic oncology group study. Cancer 118(12):3087-3094. doi: 10.1002/cncr.26618
11. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135-166
12. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82(5):893-901
13. Peng HL, He L, Zhao X (2012) Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis - results of a meta-analysis. Asian Pac J Cancer Prev 13(5):2003-2007
14. Ho CM, Cheng WF, Lin MC, Chen TC, Huang SH, Liu FS, Chien CC, Yu MH, Wang TY, Hsieh CY (2010) Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 20(9):1490-1497. doi: 10.1111/IGC.0b013e3181e68a4d
15. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS (2004) Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 15(10):1535-1542. doi: 10.1093/annonc/mdh387
16. Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, Potet F (1997) Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28(8):922-928
17. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH (2006) Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 56(2):62-70. doi: 10.1111/j.1440-1827.2006.01925.x
18. Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, Becker KF (2008) The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 98(2):489-495. doi: 10.1038/sj.bjc. 6604115
19. Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J (2010) Expression and localization of e-cadherin in epithelial ovarian cancer. Anticancer Res 30(7):2525-2530
20. Voutilainen KA, Anttila MA, Sillanpaa SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma VM (2006) Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 59(5):460-467. doi: 10.1136/jcp.2005.029876
21. Shim HS, Yoon BS, Cho NH (2009) Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol 40(5):693-698. doi: 10.1016/j.humpath.2008.10.013
22. Dian D, Bruning A, Mylonas I (2011) E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis. Arch Gynecol Obstet 284(2):437-443. doi: 10.1007/s00404-010-1657-0
23. Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A (2000) E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol 79(3):362-371. doi: 10.1006/gyno.2000.5964
24. Landen CN Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995-1005. doi: 10.1200/JCO.2006.07.9970
25. Davies BR, Worsley SD, Ponder BA (1998) Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32(1):69-80
26. Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, Oka K, Konishi I (2004) Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Human Pathol 35(12):1469-1476
27. Hudson LG, Zeineldin R, Stack MS (2008) Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Met 25(6):643-655. doi: 10.1007/s10585-008-9171-5
28. Cheung LW, Leung PC, Wong AS (2010) Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene 29(16):2427-2440. doi: 10.1038/onc.2009.523
29. Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B (2006) Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol 50(6):603-607